Risk factors
ImageneBio (IMA) risk factors
Item 1A of every ImageneBio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks71 new76 dropped9 reworded
ImageneBio completed a merger in July 2025, divested non-IMG-007 assets, and is now entirely dependent on IMG-007 for atopic dermatitis and other immunological indications.
Filed Mar 10, 2026 - FY2024 10-K risk factors85 risks
ImageneBio faces risks centered on its pending merger with Insight Merger Sub, ongoing net losses, and clinical development in targeted oncology.
Filed Mar 06, 2025